Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Bellicum Pharmaceuticals (NASDAQ:BLCM) will announce its second quarter 2020 financial results on August 6, 2020, after U.S. market close. A conference call and webcast will follow at 5 p.m. ET/2 p.m. PT to discuss results and provide a corporate update. Bellicum focuses on controllable cellular immunotherapies aimed at cancer treatment, with product candidates like GoCAR-T® designed to enhance CAR-T cell efficacy. More details can be found on their official website.
- Scheduled webcast and call indicate proactive investor communication.
- Development of next-generation CAR-T therapies may enhance future market position.
- None.
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the second quarter 2020 after the close of U.S. markets on Thursday, August 6, 2020. Management will host a webcast and conference call at 5 p.m. ET / 2 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 800-920-0677 (U.S. domestic) and 212-231-2908 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will be available for replay in the Investors & Media section of the Bellicum website following the call.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com
FAQ
When will Bellicum Pharmaceuticals report its Q2 2020 financial results?
What will be discussed during the Bellicum Pharmaceuticals conference call?
How can I access the Bellicum Pharmaceuticals conference call?
